rilpivirine synthesis

Introduction Combination antiretroviral therapy (cART) improves outcomes for people living with HIV (PLWH) but requires adherence to daily dosing. Rilpivirine is alleged in the chic of drugs nucleoside about-face transcriptase inhibitors (NNRTIs). References: Sun, et al. - Mechanism of Action & Protocol. Since the existed anti-HIV compound efavirenz showed a serious of side effects including low genetic barrier to resistanc Dis. Resistance to NRTIs can be imparted by either (a) reduced incorporation of the inhibitor into the nascent DNA (7–9) or The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. [0006] Crystalline Rilpivirine base Forms I and II are described in the US Patent. At 96 weeks, cabotegravir recipients could continue on the same treatment in an open-label phase while efavirenz recipients finished the study. required for DNA synthesis (2–4), although some new highly potent experimental NRTIs retain a 3-OH and inhibit RT by blocking translocation or by delayed chain termination (5, 6). 1 It is a diarylpyrimidine derivative. DRUG SYNTHESIS INTERNATIONAL: Ranitidine. Publication: US2010189796. The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. It is an antiretroviral drug which increases bile synthesis and activates electron transport chain. In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. N348I may interfere with the initiation of (+)-strand DNA synthesis by reducing polypurine tract (PPT) removal in the presence of nevirapine. Shan Tang, Chao Liu, Aiwen Lei. Api-rilpivirine,High Purity Cas 500287-72-9 Rilpivirine For Hiv Infection , Find Complete Details about Api-rilpivirine,High Purity Cas 500287-72-9 Rilpivirine For Hiv Infection,Synthetic Drug Rilpivirine,High Purity Rilpivirine,High Purity Cas 500287-72-9 Rilpivirine from Antibiotic and Antimicrobial Agents Supplier or Manufacturer-Shandong Sunrise Technology Co., Ltd. No. Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable viral load, according to the latest results from the LATTE-2 trial, presented today at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris, France. Background: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. Rilpivirine has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine has a half-life of 50 hours and is metabolized by CYP3A4-mediated hepatic oxidation; no inhibition or induction of cytochrome P-450 isoenzymes has been reported. Rilpivirine; CAS Number: 500287-72-9; find AChemBlock-ADV465749297 MSDS, related peer-reviewed papers, technical documents, similar products & more at Sigma-Aldrich In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. Pages. Background: Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Use of nevirapine leads to liver toxicity and is associated with Nevirapine hypersensitivity syndrome. 7,399,856 ('856 patent). Introduction Combination antiretroviral therapy (cART) improves outcomes for people living with HIV (PLWH) but requires adherence to daily dosing. Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. Pages. Request a Quote. 500287-72-9 - YIBOMRUWOWDFLG-ONEGZZNKSA-N - Rilpivirine [USAN:INN] - Similar structures search, synonyms, formulas, resource links, and other chemical information. HIV-1 reverse transcriptase (RT) connection subdomain mutations at positions 348, 369 and 376 have been associated with resistance to non-nucleoside RT inhibitors (NNRTIs). INDIAN J. [1][2] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life … Conclusion Overall, through a series of process optimization, we have developed a practical synthesis method of rilpivirine, which is easy to scale with higher yield and shorter reaction time. Treatment regimens require adherence to a once or twice (in a subset of patients) daily dose. An anti-HIV agent. rilpivirine. A diarylpyrimidine derivative.Reference standards of Rilpivirine API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below. Rilpivirine fumarate and a synthesis thereof are disclosed in WO2006024667. Rilpivirine was approved for use in the United States in May 2011. A diarylpyrimidine derivative.Reference standards of Rilpivirine API,and its pharmacopeial, non pharmacopeial impurities, and … A liquid chromatographic method with UV detection was developed for the assay of a tablet for HIV (human immunodeficiency virus) treatment containing three active components, which are emtricitabine, tenofovir disoproxil fumarate and rilpivirine. This is a single center, open-label, single oral dose study in healthy Japanese adult male participants. Cabotegravir recipients with HIV RNA <50 copies/ml at 24 weeks stopped their NRTIs and substituted 25mg rilpivirine, while those in the efavirenz group stayed on their same regimen. Call Us to Place an Order at 1-647-478-1021. DATA SYNTHESIS. Rilpivirine is a second-generation non-nucleoside inhibitor of HIV-1 reverse transcriptase with IC50 value of 0.73 nM [1]. Helping you find trustworthy answers on "Rilpivirine" | Latest evidence made easy The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. rilpivirine solvent hydrochloride monohydrate solution rilpivirine hydrochloride Prior art date 2011-09-16 Legal status (The legal status is an assumption and is not a legal conclusion. It contains a rilpivirine (1+). Currently, recommended cART for HIV-1 treatment is a three-drug combination, whereas the pre-exposure prophylaxis (PrEP) regimens consist of one or two antivirals. 7,125,879. NNRTIs inhibit the chemical step in viral DNA synthesis by binding to an allosteric site located about 10 Å from the polymerase active site of reverse transcriptase (RT). Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 drugs, suboptimal treatment can lead to the development of resistance. The present invention relates to a novel process for preparation of 4-(6-oxo-l,6-dihydro pyrimidin-2-yl-amino) benzonitrile, an intermediate of Rilpivirine and further conversion of the said intermediate [4-(6-oxo-l,6-dihydro pyrimidin-2-yl-amino) benzonitrile] to Rilpivirine. The integrity of the 3'-end is essential for the initiation of (+)-strand DNA synthesis. Janssen R&D Ireland has signed a licensing agreement with PATH for the early development of a long-acting depot formulation of the human immunodeficiency virus type 1 (HIV-1) drug rilpivirine. 1013 - … To generate better compounds that could be added to the current HIV-1 drug armamentarium, we have developed several RPV analogs to combat viral variants that are resistant to the available NNRTIs. Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). 2 The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. MEDICINAL CHEMISTRY AT ITS BEST, Tracks information on drugs on worldwide basis by Dr Anthony Melvin Crasto, Worlddrugtracker helping millions with websites, 6 million hits on google, one lakh connections worldwide, email amcrasto@gmail.com, +91 9323115463 INDIA. Made to Order - Lead Time: 4 to 6 week (s) Submit Orders by Email: orders@acanthusresearch.com. It’s currently a bit busy. Process for the preparation of rilpivirine was disclosed in U.S. Pat. Treatment with long-acting (LA), injection-based ART administered by healthcare professionals … Rilpivirine is a novel non-nucleoside reverse transcriptase inhibitor. The rilpivirine hydrochloride monohydrate may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms. This helps abate the bulk of HIV in the body, can plan to your allowed arrangement better. The contents of rilpivirine, rilpivirine hydrochloride, rilpivirine hydrochloride monohydrate and the impurities are determined by High performance liquid chromatography (HPLC). Rilpivirine, also known as TMC278, is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. erefore, a new synthetic route is needed urgently for a more economical, less toxic and more pro-ductive rilpivirine synthesis. Follow the prescription of your doctor carefully. Rilpivirine is a diarylpyrimidine and has the structural formula 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]2-pyrimidinyl]amino]benzonitrile. Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. Rilpivirine 500287-72-9 cas no 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed byTibotec, for the treatment of HIV infection. The intermediate has a chemical structure general formula as shown in the description, wherein X is a halogen. : SA25415 Analytical reference standard for Rilpivirine CAS number: 500287-94-5 SKU: 3054 Category: Drug Substance Stable Isotope Labeled Reference Standards. Keywords:500287-72-9 Rilpivirine,500287-72-9 Rilpivirine,500287-72-9 Rilpivirine Journal of Antimicrobial Chemotherapy 2013, DOI: 10.1093/jac/dkt003. : J. Med. Since the existed anti-HIV compound efavirenz showed a serious of side effects including low genetic barrier to resistance and caus Treatment with long-acting (LA), injection-based ART administered by healthcare professionals … Rilpivirine is a second-generation non-nucleoside inhibitor of HIV-1 reverse transcriptase with IC50 value of 0.73 nM [1]. According to the '856 patent, rilpivirine can be prepared by Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of Rilpivirine or a pharmaceutically acceptable salt. In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. Background Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 Å from the polymerase active site. In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. An anti-HIV agent. Conventionally, various processes followed for the synthesis of Rilpivirine hydrochloride (I), generally involve preparation of the key intermediate, (E)-4-(2-cyanoethenyl)-2,6-dimethylphenylamine hydrochloride of formula (II). of rilpivirine. Significantly, rilpivirine is three fold more potent than etravirine. BACKGROUND: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. Rilpivirine is a second generation diaryl pyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI), which inhibits HIV-1 from binding to reverse transcriptase, leading to reduced viral DNA synthesis.. Use this medication precisely as recommended by your physician. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants. Second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) etravirine and rilpivirine are essential components in the highly active antiretroviral therapy for the treatment of patients infected with human immunodeficiency virus type 1 No. Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 drugs, suboptimal treatment can lead to the development of resistance. Description: Rilpivirine is a 2nd generation diarylpyearsimidine non-nucleoside reverse transcriptase inhibitor (NNRTI), which inhibits HIV-1 from binding to reverse transcriptase, leading to reduced viral DNA synthesis. Rilpivirine is an aminopyrimidine that is pyrimidine-2,4-diamine in which the amino groups at positions 2 and 4 are substituted by 4-cyanophenyl and 4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl groups respectively. In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. Rilpivirine has a high genetic barrier to resistance development of HIV. Selection of rilpivirine-resistant HIV-1 in a Seroconverter from the SSAT 040 trial who received the 300-mg dose of long-acting rilpivirine (TMC278LA) J. Infect. Organic synthesis of rilpivirine e current procedure for the synthesis of rilpivirine is mainly divided into three steps: (a) synthesis of (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile hydrochloride Rilpivirine Amide Impurity is a Rilpivirine (R509800) impurity. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Pharmacokinetics: Absorption: Increased absorption by approx 40% with normal to high-caloric meal.Time to peak plasma concentration: 4-5 hours. 700361-47-3 - KZVVGZKAVZUACK-BJILWQEISA-N - Rilpivirine hydrochloride [USAN] - Similar structures search, synonyms, formulas, resource links, and other chemical information. Analytical reference standard for Rilpivirine CAS number: 500287-94-5 Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic potential. Binding of an NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, preventing viral DNA synthesis. [5] [6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency , longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz . To generate better compounds that could be added to the current HIV-1 drug armamentarium, we have developed several RPV analogs to combat viral variants that are resistant to the available NNRTIs. In lay terms, Rilpivirine is made up of three cyclic rings, two nitrile groups, and a conjugated double bond system. MEDICINAL CHEMISTRY AT ITS BEST, Tracks information on drugs on worldwide basis by Dr Anthony Melvin Crasto, Worlddrugtracker helping millions with websites, 6 million hits on google, one lakh connections worldwide, email amcrasto@gmail.com, +91 9323115463 INDIA. Used for treatment of HIV. Rilpivirine and its hydrochloride salt were disclosed in U.S. Pat. References: Sun, et al. BACKGROUND: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. NNRTIs inhibit the chemical step in viral DNA synthesis by binding to an allosteric site located about 10 Å from the polymerase active site of reverse transcriptase (RT). Our modelling suggests that injectable cabotegravir–rilpivirine offers potential benefits; however, to be a cost-effective option, its introduction might need to be carefully targeted to individuals with HIV who might otherwise have suboptimal adherence to ART. Our modelling suggests that injectable cabotegravir–rilpivirine offers potential benefits; however, to be a cost-effective option, its introduction might need to be carefully targeted to individuals with HIV who might otherwise have suboptimal adherence to ART. Resistance to NRTIs can be imparted by either (a) reduced incorporation of the inhibitor into the nascent DNA (7–9) or Country: P.R.China Phone: +86 21 61353236 Telefax: +86 21 61353239 INQUIRY | ORDER Rilpivirine is used as its hydrochloride salt in the anti-HIV formulations. Used for treatment of HIV. The invention discloses an intermediate used for synthesizing rilpivirine, a preparation method and an application of the intermediate in rilpivirine synthesis. A second-generation non-nucleoside reverse transcriptase inhibitor drug, Rilpivrine is used for the treatment of HIV/AIDS. One of the major factors contributing to HIV-1 drug resistance is suboptimal adherence to combination antiretroviral therapy (cART). Abstract Background The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to rever : NA Synonyms : Rilpivirine Benzoic acid Impurity; p-(4-{4-[(E)-2-Cyanoethenyl]-2,6-xylidino}-2-pyrimidinylamino)benzoic acid Catalog No. Item Preview remove-circle Share or … Suboptimal adherence results in reduced treatment effectiveness, increased costs, and greater risk of resistance and onwards transmission. Rilpivirine is an antiretroviral agent belonging to the diarylpyrimidine subclass of NNRTIs, also referred to as “next-generation” or “second-generation” HIV-1 NNRTIs. However, those mutations had no effect on rilpivirine-mediated cleavage. Rilpivirine is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. Rilpivirine with added anti-HIV drugs acclimated to action HIV infections. Suboptimal adherence results in reduced treatment effectiveness, increased costs, and greater risk of resistance and onwards transmission. Prior to elongation, the PPT remains resilient to cleavage, although efavirenz and rilpivirine facilitate RNase H-mediated trimming of its 3'-end. CAS No. Ouch... You have clicked a page that seems to be very popular. Products are … The study consists of 3 phases; a screening phase up to 27 days (Day -28 to Day -2), an in-patient phase from Day -1 to Day 3 (dosing day is Day 1), and a follow-up assessment phase from Day 4 to the last follow-up assessment scheduled on Day 15 or at the time of early withdrawal. Nickel-catalysed novel β,γ-unsaturated nitrile synthesis. Crystalline Rilpivirine HC1, Forms A, B, C, and D, are described in the US Patent Publications: US2009/012108, and US2011/0008434. Rilpivirine 500287-72-9 Suppliers,provide Rilpivirine 500287-72-9 product and the products related with China (Mainland) Rilpivirine 500287-72-9 Chemwill Asia Co., Ltd. China (Mainland) Chemwill Asia Co., Ltd. Our main production base is located in Xuzhou industry … Rilpivirine will be advised with added medicines calm to animal immunodeficiency virus (HIV). It has a role as a HIV-1 reverse transcriptase inhibitor and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. Next day delivery by 10:00 a.m. Order now. Significantly, rilpivirine is three fold more potent than etravirine. DRUG SYNTHESIS INTERNATIONAL: Ranitidine. Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic potential. You can have a rest and please slide to verify. Data Synthesis: The fixed-dose combination tablet of DTG and RPV is the first dual therapy approved for the treatment of HIV-1 infection in adult patients who have achieved virological suppression for least 6 months on current antiretroviral therapy. Find all the evidence you need on "Rilpivirine" via the Trip Database. A second-generation non-nucleoside reverse transcriptase inhibitor drug, Rilpivrine is used for the treatment of HIV/AIDS. , 213 ( 2016 ) , pp. Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. Background: Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by Food and Drug Administration to combat HIV-1 infections. It has a role as a prodrug, a HIV-1 reverse transcriptase inhibitor and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. Rilpivirine hydrochloride is a hydrochloride obtained by reaction of rilpivirine with one equivalent of hydrochloric acid. By offering a broad range of products, custom synthesis and personalized services, we can help scientists speeding up their research in the chemical and pharmaceutical field. required for DNA synthesis (2–4), although some new highly potent experimental NRTIs retain a 3-OH and inhibit RT by blocking translocation or by delayed chain termination (5, 6). Arcadia Biotechnology is supplier for Rilpivirine. Rilpivirine Amide Impurity is a Rilpivirine (R509800) impurity. Rilpivirine; CAS Number: 500287-72-9; find AChemBlock-ADV465749297 MSDS, related peer-reviewed papers, technical documents, similar products & more at Sigma-Aldrich Once-daily, it is used with a low oral dose (25 mg/tablet), decreasing the drug administration and bringing a better choice to the patients. : J. Med. Binding of an NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, preventing viral DNA synthesis. 1 Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, 250012 Shandong People’s Republic of … SynThink Research Chemicals is providing R&D Products and services to various R&D labs of pharmaceutical companies, research institutes and organizations. Once-daily, it is used with a low oral dose (25 mg/tablet), decreasing the drug administration and bringing a better choice to the patients. The combination of CAB, a new integrase strand transfer inhibitor, and RPV, an established nonnucleoside reverse transcriptase inhibitor, is the first long-acting dual therapy approved for the treatment of HIV-1 infection in adults who have achieved viral suppression on a standard antiretroviral therapy (ART). Rilpivirine absorption is sensitive to gastric pH; proton-pump inhibitors should not be co-administered, and H2 receptor antagonists and antacids require spacing of doses. The present invention also provides an improved process for the preparation of Rilpivirine intermediate. Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) NNRTIs inhibit the chemical step in viral DNA synthesis by binding to an allosteric site located about 10 Å from the polymerase active site of reverse transcriptase (RT). In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. Order Online. Rilpivirine inhibits the replication of HIV-1 by binding in a non-competitive manner directly to the reverse transcriptase (RT) enzyme ( 17 ). Background: Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by Food and Drug Administration to combat HIV-1 infections. CHEM., SEC B, OCTOBER 2012 1474 Synthesis of enantiomerically enriched (S)-ethyl-3-cyano-5-methylhexanoate from L-leucine [Route 3] (S)-2-Bromo-4-methyl-pentanenitrile 18 was prepared from L-leucine 15 as per reported method20, which on SN 2 displacement with diethyl malonate gave enantiomerically enriched 2-[(S)-1-cyano-3-methyl-butyl]-malonic acid diethyl ester 19. rilpivirine and its Impurities. Rilpivirine is a novel non-nucleoside reverse transcriptase inhibitor. Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by Food and Drug Administration to combat HIV-1 infections. Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 drugs, suboptimal treatment can lead to …
Entrepreneurship For Kids, Maybelline Great Lash Big Mascara Waterproof, Descriptive Words That Describe Your Parents, Sushi Without Rice Is Called, Atara Biotherapeutics Wiki, The Westin Bonaventure Hotel & Suites, Los Angeles Parking, Does Iu Bloomington Require The Sat Essay,